论文部分内容阅读
血小板生成素(以下简称TPo)是属于α球蛋白领域的糖蛋白;现在还查明其分子量约为25,000; 虽有抗原性,但在小鼠和人之间无种特性异。著者使用了由人血清中提纯的TPo成功地培育出巨核细胞集落(CFU-M),显而易见,这一事实预示了在血小板增加或减少的各种疾病时人TPo活性体外定量检查的可能性。又由于人巨核细胞集落的培育成功,不仅有可能阐明TPo的作用机制,而且有可能进行巨核细胞前身细胞定量,揭示巨核细胞——血小板系统的细胞周期以及阐明血小板生成的机制。至于说TPo的产生部位,有报告称,在人胎儿肾细胞培养上清液中进行免疫学和生物学检查时,发现具有TPo活性;另外,在实验动物中,与其他
Thrombopoietin (hereinafter referred to as TPo) belongs to the field of α-globulin glycoprotein; now it is also identified that its molecular weight is about 25,000; although antigenicity, but no species-specific differences between mice and humans. The fact that the authors succeeded in developing megakaryocyte colonies (CFU-M) using TPo purified from human serum clearly indicates the possibility of in vitro quantitative testing of human TPo activity in various diseases with increased or decreased platelets. In addition, because of the successful cultivation of human megakaryocyte colonies, it is not only possible to elucidate the mechanism of action of TPo, but also to quantify precursor cells of megakaryocytes, reveal the cell cycle of megakaryocyte-platelet system, and elucidate the mechanism of platelet production. As for the site of TPo production, it has been reported that TPo activity was found in immunological and biological tests in human fetal kidney cell culture supernatants; in addition, in experimental animals,